Get started
Author

Rajendra Prasad Sarkar

Observed names: R. Sarkar, R.P. Sarkar, SARKAR R.
Institution: Novartis (India)
ORCID: 0000-0002-6755-7300
Observed ORCID: 0000-0002-6755-7300
OpenAlex ID: A5088380665
A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S)
2020 · Joel M. Gelfand, Daniel B. Shin, et al. · Journal of Investigative Dermatology · 102
PDF
Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study
2023 · Andrew Blauvelt, David M. Pariser, et al. · Journal of Dermatological Science · 18
PDF
Effectiveness of cyclosporine A in patients with moderate to severe plaque psoriasis in a real-life clinical setting in Italy: the TRANSITION study
2020 · F. Marsili, M. Travaglini, et al. · Journal of Dermatological Treatment · 12
PDF
819P Efficacy of dabrafenib (D) trametinib (T) plus spartalizumab (S) by baseline site of metastases in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Post hoc analysis of phase III COMBI-i trial
2022 · P. Nathan, J.J. Grob, et al. · Annals of Oncology · 3
PDF
P1491: Real-world Incidence of Vaso-occlusive Crises in Patients With Sickle Cell Disease (scd) and a High Baseline Disease Burden Treated With Crizanlizumab: Results From a Managed Access Program (map)
2022 · A. C. Silva-Pinto, R. Colombatti, et al. · HemaSphere · 1
O-04: Incidence of Vaso-occlusive Crises in Patients With Sickle Cell Disease (scd) and a High Baseline Disease Burden Treated With Crizanlizumab in a Real-world Setting: Results From a Managed Access Program (map)
2022 · SILVA-PINTO A., COLOMBATTI R., et al. · HemaSphere
P1389: Ruxolitinib Demonstrates a Greater Corticosteroid-sparing Effect Than Best Available Therapy in Patients With Corticosteroid-refractory/dependent Chronic Graft-vs-host Disease
2022 · R. Zeiser, D. Russo, et al. · HemaSphere
Works count: 7
Citation count: 136
H-index: 3
I10-index: 3
Year
Topic
Type